Heron Therapeuti

Yahoo Finance • 2 months ago

Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment

Earnings Call Insights: Heron Therapeutics (HRTX) Q4 2025 MANAGEMENT VIEW * CEO Craig Collard emphasized the "successful completion of our financing," describing it as a "meaningful derisking event" that enables the company to focus on... Full story

Yahoo Finance • 4 months ago

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker onset than oral aprepitant Aprepitant al... Full story

Yahoo Finance • 6 months ago

Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. C... Full story

Yahoo Finance • 6 months ago

Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on... Full story

Yahoo Finance • 8 months ago

Rubric capital buys Heron Therapeutics (HRTX) shares worth $3.5m

Rubric Capital Management LP, a ten percent owner of HERON THERAPEUTICS, INC. /DE/ (NASDAQ:HRTX), acquired 2,387,225 shares of common stock at $1.50 per share, for a total transaction value of $3,580,837. The purchase comes as the stock tr... Full story

Yahoo Finance • 8 months ago

Heron Therapeutics raises adjusted EBITDA guidance to $9M-$13M for 2025 amid commercial restructuring and ZYNRELEF J-code milestone

Earnings Call Insights: Heron Therapeutics (HRTX) Q2 2025 MANAGEMENT VIEW * CEO Craig Alexander Collard highlighted the successful completion of new financing as “one of the most significant milestones this quarter,” stating it “streng... Full story

Yahoo Finance • 8 months ago

These stocks are moving in today's session

Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report. [topmovers] TOP GAINERS TICKER CHANGE COMMENT SGBX [https://w... Full story

Yahoo Finance • 8 months ago

Traders are paying attention to the gapping stocks in Friday's session.

The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. [gap] TOP GAP UP STOCKS TICKER CHANGE COMMENT ORIS [http... Full story

Yahoo Finance • 8 months ago

Heron Therapeutics Completes Capital Restructuring

Heron Therapeutics (HRTX) said Friday it has completed its capital restructuring to boost financial PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 8 months ago

Heron Therapeutics GAAP EPS of -$0.02 misses by $0.01, revenue of $37.2M misses by $0.88M

* Heron Therapeutics press release [https://seekingalpha.com/pr/20194787-heron-therapeutics-announces-q2-2025-financial-results-and-highlights-commercial-progress] (NASDAQ:HRTX [https://seekingalpha.com/symbol/HRTX]): Q2 GAAP EPS of -$0.... Full story

Yahoo Finance • 2 years ago

Heron Therapeutics, Inc. (NASDAQ:HRTX) is largely controlled by institutional shareholders who own 52% of the company

Key Insights Institutions' substantial holdings in Heron Therapeutics implies that they have significant influence over the company's share price The top 9 shareholders own 53% of the company Insiders have bought recently A look at the s... Full story

Yahoo Finance • 2 years ago

Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

Heron is increasing full-year 2023 Net Product Sales guidance for the oncology care franchise to a range of $104 million to $106 million from a prior range of $99 million to $103 million We anticipate full-year 2023 Net Product Sales to be... Full story

Yahoo Finance • 3 years ago

Why Heron Therapeutics Stock Has Been on Fire This Week

Shares of Heron Therapeutics (NASDAQ: HRTX) stormed higher by 47% over the first 3 1/2 days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain came in response to the appointment of Craig Colla... Full story

Yahoo Finance • 3 years ago

Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023

SAN DIEGO, March 13, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most impor... Full story

Yahoo Finance • 3 years ago

12 Best Affordable Stocks to Buy Under $5

In this article, we discuss 12 best affordable stocks to buy under $5. If you want to see more stocks in this selection, check out 5 Best Affordable Stocks to Buy Under $5. Third Point, a New York-based financial advisor, published its th... Full story

Yahoo Finance • 4 years ago

Heron Therapeutics to cut about one-third of its workforce as part of cost-cutting plan

Heron Therapeutics Inc. said Thursday it will lay off about one-third of its workforce as part of a restructuring expected to save $43 million a year. The biotechnology company's stock was still inactive in premarket trading. The company s... Full story

Yahoo Finance • 4 years ago

10 Most Shorted Stocks to Watch

In this article, we discuss the 10 most shorted stocks to watch today. To take a look at some more stocks, go directly to the 5 Most Shorted Stocks to Watch. The US stock market has been in a correction mode as the S&P 500 Index and the D... Full story